A 25-year-old woman with progressive Raynaud’s phenomenon and digital necrosis is presented. Systemic sclerosis and other connective tissue disorders as well as atherosclerosis and arterial emboli were excluded with appropriate laboratory examinations. Arteriography revealed multiple palmar and digital occlusions with corkscrew-shaped vessels. Based on these characteristic arteriographic and clinical findings, the diagnosis of thromboangiitis obliterans was finally retained. With intravenous perfusion of the prostacyclin analogue iloprost (2 ng/kg/min, 6 h daily during 21 days), a complete healing of Raynaud’s phenomenon and of the digital necrosis was observed. There was no recurrence during the 1-year follow-up. This observation demonstrates that thromboangiitis obliterans is a potential reversible cause of severe Raynaud’s phenomenon in young women even in the absence of lower limb involvement. Early recognition is important to avoid irreversible complications such as loss of digits.

Keywords:
Raynaud’s phenomenon, Thromboangiitis obliterans, Iloprost
1.
Borner C, Heidrich H: Long-term follow-up of thromboangiitis obliterans. Vasa 1998;27:80–86.
2.
Michail PO, Filis KA, Delladetsima JK, Koronarchis DN, Bastounis EA: Thromboangiitis obliterans (Buerger’s disease) in visceral vessels confirmed by angiographic and histological findings. Eur J Vasc Endovasc Surg 1998;16:445–448.
3.
Lie JT: Visceral intestinal Buerger’s disease. Int J Cardiol 1998;66(suppl 1):S249–S256.
4.
Bischof F, Kuntz R, Melms A, Fetter M: Cerebral vein thrombosis in a case with thromboangiitis obliterans. Cerebrovasc Dis 1999;9:295–297.
5.
Sasaki S, Sakunma M, Kunihara T, Yasuda K: Current trends in thromboangiitis obliterans (Buerger’s disease) in women. Am J Surg 1999;177:316–320.
6.
Disdier P, Swiader L, Jouglard J, Piquet P, Christides C, Moulin G, Harle JR, Weiller PJ: Cannabis-induced arteritis vs. Leo Buerger disease: Nosologic discussion à propos of two new cases. Presse Méd 1999;28:71–74.
7.
Tanaka K: Pathology and pathogenesis of Buerger’s disease. Int J Cardiol 1998;66(suppl 1):S237–S242.
8.
Mozes M, Cahanski G, Doitsh V, Adar R: The association of atherosclerosis and Buerger’s disease: A clinical and radiological study. J Cardiovasc Surg 1970;11:52–59.
9.
Suzuki S, Yamada I, Himeno Y: Angiographic findings in Buerger disease. Int J Cardiol 1996;54(suppl 1):89–95.
10.
Van Damme H, De Leval L, Creemers E, Limet R: Thrombangiitis obliterans (Buerger’s disease): Still a limb threatening disease. Acta Chir Belg 1997;97:229–236.
11.
Borner C, Heidrich H: Long-term follow-up of thromboangiitis obliterans. Vasa 1998;27:80–86.
12.
Lau H, Cheng SW: Buerger’s disease in Hong Kong: A review of 89 cases. Aust NZ J Surg 1997;67:264–269.
13.
Shigematsu H, Shigematsu K: Factors affecting the long-term outcome of Buerger’s disease (thromboangiitis obliterans). Int Angiol 1999;18:58–64.
14.
Ishibashi H, Hayakawa N, Yamamoto H, Nishikimi N, Yano T, Nimura Y: Thoracoscopic sympathectomy for Buerger’s disease: A report on the successful treatment of four patients. Surg Today 1995;25:180–183.
15.
Lau H, Cheng SW: Buerger’s disease in Hong Kong: A review of 89 cases. Aust NZ J Surg 1997;67:264–269.
16.
Nakajima N: The change in concept and surgical treatment on Buerger’s disease – Personal experience and review. Int J Cardiol 1998;66(suppl 1):S273–S280, discussion S281.
17.
Grant SM, Goa KL: Iloprost: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889–924.
18.
Fiessinger JN, Schafer M: Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans: The TAO Study. Lancet 1990;335:555–557.
19.
Caspary L, Creutzig A, Alexander K: Intravenous infusion of iloprost in arterial occlusive disease: Dose-dependent effects on skin microcirculation. Eur J Clin Pharmacol 1991;41:131–136.
20.
Melillo E, Iabichella L, Berchiolli R, Ferrari M, Catapano G, Dell’Omo G, Pedrinelli R: Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Int J Microcirc Clin Exp 1995;15:60–64.
21.
Biasi D, Carletto A, Caramaschi P, Zeminian S, Pacor ML, Corrocher R, Bambara LM: Iloprost as cyclic five-day infusions in the treatment of scleroderma: An open pilot study in 20 patients treated for one year. Rev Rhum Engl Ed 1998;65:745–750.
22.
Black CM, Halkier-Sorensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR: Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37:952–960.
23.
Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, Murphy E, Steinberg M: Oral iloprost as a treatment for Raynaud’s syndrome: A double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197–200.
24.
The European TAO Study Group: Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): A double-blind, randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 1998;15:300–307.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.